Website Search
Find information on spaces, staff, and services.
Catalog Search
Books
Socio-economics of personalized medicine in Asia
- Author / Creator
- Available as
- Online
- Summary
-
"The second decade of the 21st century has witnessed a new surge in emphasis on personalized medicine based on analysis of an individual's unique genetic make-up as a means to enable more precise d...
"The second decade of the 21st century has witnessed a new surge in emphasis on personalized medicine based on analysis of an individual's unique genetic make-up as a means to enable more precise diagnosis, treatment and prevention of diseases. This book attempts to contribute to this growing body of literature by tracing and analyzing "personalized medicine" as it unfolds in Asia, and in so doing, illustrating various social forces shaping the "co-production" of science and social order in transnational settings. The book shows that there are inextricable transnational linkages between developing and developed countries and also provides a theoretically guided and empirically grounded understanding of the formation and usage of particular human taxonomies in transnational settings"--
Details
- Creator
- Shirley Sun
- Format
- Books
- Language
- English
- Publication
-
- New York : Routledge, 2017
- Physical Details
-
- 1 online resource (211 p.)
- ISBNs
- 9781134989195, 1134989199, 9781315537177, 1315537176, 9781134989126, 1134989121, 036735442X, 113893383X
- OCLC
- ocn953054607
- Includes index.
- English
- Cover; Title; Copyright; Dedication; Contents; Acknowledgments; 1 Introduction; Personalized medicine and population-based research and development; What is a population? Race and genetics in North America; Personalized medicine, pharmacogenomics, and pharmacoethnicity; Why Asia?; Time, space, and the emergent other; Genomics in Asia and the unfolding dynamics of othering; Current research infrastructure and development concerning personalized medicine in Asia; Existing social-science studies of science and medicine performed in Asia; The illuminating question could be, when are you from?
- What is at stake when populations are ethnically or racially labeled?Chapter outline; 2 Regionalism and the study of human genetic variation in a transnational context: Asianism, nationalism, and the racialization of ethnicity; Introduction; The fundamental question of, when are you from?; Once upon a time: the unfolding character of the "Japanese" category; Effects of Japanese colonialism and regional integration on the notion of "Japanese"; Resisting being "othered": scientists in Asia define "Asian" genome diversity
- Ethnicity as a proxy for genetic diversity and the molecularization of ethnicities in AsiaConclusion; 3 Capitalizing on being "othered": precision medicine and race in the context of a globalized pharmaceutical industry; Introduction; Saving IRESSA; The larger significance of the story of IRESSA; Racializing clinical trials as a routine phenomenon; Local transformations; Pharmacogenomics, race, and post-marketing clinical trials; Conclusion; 4 Managing otherness: genomics and public health policy in Singapore; Introduction; Population aggregate data, ethnicity, and post-market drug vigilance
- Irinotecan and UGT1A1 genotypingCarbamazepine and HLA-B*1502 genotyping; Analysis of the prevailing practices noted above; The historical emergence of "Malay" as a group during the precolonial era; "Malayness" during the colonial era; "Malayness" in the Malay Peninsula in the postcolonial era; The case of the Malay in Singapore; Conclusion; 5 Cancer genomics in clinics; Introduction; Using ethnicity or race as a basis of clinical decision-making; Personalized medicine in clinical practice: drug efficacy; Personalized medicine in clinical practice: drug toxicities
- Personalized medicine in clinical practice: preventive medicineConclusion; 6 Socio-economic factors and ethical dilemmas in personalized medicine provision; Introduction; Genome-based personalized medicine is effective but not curative; moreover, it can be prohibitively expensive; Should the cost of a cancer drug be part of the treatment decisions?; Who should be expected to interpret genetic tests when cancer is a "context-dependent manifestation"?; Privacy concerns and the potential for genetic discrimination at the level of the individual and the group
- Should genome-based pharmaceuticals be the primary approach to treating cancer?